{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:15:52Z","timestamp":1761765352477},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T00:00:00Z","timestamp":1291248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s11934-010-0157-x","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T05:40:17Z","timestamp":1291182017000},"page":"77-85","source":"Crossref","is-referenced-by-count":12,"title":["Overactive Bladder and Outlet Obstruction in Men"],"prefix":"10.1007","volume":"12","author":[{"given":"Doreen E.","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet S.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,2]]},"reference":[{"key":"157_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003, 61:37\u201349.","journal-title":"Urology"},{"key":"157_CR2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11934-005-0034-1","volume":"6","author":"WI Jaffe","year":"2005","unstructured":"Jaffe WI, Te AE: Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 2005, 6:410\u2013418.","journal-title":"Curr Urol Rep"},{"key":"157_CR3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50:1306\u20131314.","journal-title":"Eur Urol"},{"key":"157_CR4","volume-title":"Urology","author":"R Kirby","year":"2007","unstructured":"Kirby R, Lepor H: Evaluation and non-surgical management of benign prostatic hyperplasia, in Wein A, Kavoussi L, Novick A, et al., Urology, 9th ed. Philadelphia, Saunders Elsevier, 2007","edition":"9"},{"key":"157_CR5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11934-002-0095-3","volume":"3","author":"KF Abdel-Aziz","year":"2002","unstructured":"Abdel-Aziz KF, Lemack GE: Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002, 3:445\u2013451.","journal-title":"Curr Urol Rep"},{"issue":"6A Suppl","key":"157_CR6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-4295(97)00587-6","volume":"50","author":"WC Groat de","year":"1997","unstructured":"de Groat WC: A neurologic basis for the overactive bladder. Urology 1997, 50(6A Suppl):36\u201352","journal-title":"Urology"},{"key":"157_CR7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(01)05549-0","volume":"358","author":"MJ Drake","year":"2001","unstructured":"Drake MJ, Mills IW, Gillespie JI: Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001, 358:401\u2013403.","journal-title":"Lancet"},{"key":"157_CR8","volume-title":"Campbell\u2019s Urology","author":"E McGuire","year":"1986","unstructured":"McGuire E: Neuromuscular dysfunction of the lower urinary tract in Walsh P, Gittes R, Perlmutter A, Stamey T: Campbell\u2019s Urology. Philadelphia, W. B. Saunders, 1986."},{"key":"157_CR9","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"\u2022\u2022 Kaplan SA, Roehrborn CG, Rovner ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296:2319\u20132328. This is the only placebo-controlled study published on combination therapy with \u03b1-blockers and antimuscarinic agents.","journal-title":"JAMA"},{"key":"157_CR10","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.juro.2008.03.142","volume":"179","author":"SA Kaplan","year":"2008","unstructured":"Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2008, 179:S82\u201385.","journal-title":"J Urol"},{"key":"157_CR11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","volume":"175","author":"P Abrams","year":"2006","unstructured":"\u2022\u2022 Abrams P, Kaplan S, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006, 175:999\u20131004. This study is one of the few to investigate the effects of antimuscarinic therapy in patients with urodynamic BOO.","journal-title":"J Urol"},{"key":"157_CR12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","volume":"94","author":"JY Lee","year":"2004","unstructured":"Lee JY, Kim HW, Lee SJ, et al.: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU International 2004, 94:817\u2013820.","journal-title":"BJU International"},{"key":"157_CR13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","volume":"49","author":"CR Chapple","year":"2006","unstructured":"Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006, 49:651\u2013659.","journal-title":"Eur Urol"},{"key":"157_CR14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0022-5347(05)64688-5","volume":"168","author":"GE Venrooij Van","year":"2002","unstructured":"Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA: Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002, 168:605\u2013609.","journal-title":"J Urol"},{"key":"157_CR15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ucl.2009.07.002","volume":"36","author":"JL Mehdizadeh","year":"2009","unstructured":"Mehdizadeh JL, Leach GE: Role of invasive uodynamic testing in benign prostatic hyperplasia and male lower urinary tract symptoms. Urol Clin N Am 2009, 36:431\u2013441.","journal-title":"Urol Clin N Am"},{"key":"157_CR16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.urology.2005.08.015","volume":"67","author":"N Seki","year":"2006","unstructured":"Seki N, Kai N, Seguchi H, et al.: Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology 2006, 67:306\u2013310.","journal-title":"Urology"},{"key":"157_CR17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/nau.10057","volume":"21","author":"R Machino","year":"2002","unstructured":"Machino R, Kakizaki H, Ameda K, et al.: Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn 2002, 21:444\u2013449.","journal-title":"Neurourol Urodyn"},{"key":"157_CR18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, et al.: The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in menand women: results from the EPIC study. BJU International 2008, 101:1388\u20131395.","journal-title":"BJU International"},{"key":"157_CR19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1464-410X.2009.08369.x","volume":"103","author":"CC Sexton","year":"2009","unstructured":"Sexton CC, Coyne KS, Kopp ZS, et al.: The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009, 103:12\u201323.","journal-title":"BJU Int"},{"key":"157_CR20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","volume":"170","author":"AUA Practice Guidelines Committee","year":"2003","unstructured":"AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530\u2013547.","journal-title":"J Urol"},{"key":"157_CR21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000049784","volume":"40","author":"JJ Rosette de la","year":"2001","unstructured":"de la Rosette JJ, Alivizatos G, Madersbacher S, et al.: EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001, 40:256\u2013263.","journal-title":"Eur Urol"},{"key":"157_CR22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0022-5347(05)65982-4","volume":"166","author":"MJ Hyman","year":"2001","unstructured":"Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001, 166:550\u2013552.","journal-title":"J Urol"},{"key":"157_CR23","first-page":"139","volume":"3","author":"CG Roehrborn","year":"2001","unstructured":"Roehrborn CG: Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options. Rev Urol 2001, 3:139\u2013145.","journal-title":"Rev Urol"},{"key":"157_CR24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0090-4295(86)90058-0","volume":"28","author":"AJ Ball","year":"1986","unstructured":"Ball AJ, Smith PJ: Urodynamic factors in relation to outcome of prostatectomy. Urology 1986, 28:256\u2013258.","journal-title":"Urology"},{"key":"157_CR25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0090-4295(03)00511-9","volume":"62","author":"GE Venrooij van","year":"2003","unstructured":"van Venrooij GE, van Melick HH, Boon TA: Comparison of ourcomes of transurethral resection of the prostate in urodynamically obstructed versus selected urodynamically unobstructed or equivocal men. Urology 2003, 62:672\u2013676.","journal-title":"Urology"},{"key":"157_CR26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0090-4295(96)00040-4","volume":"47","author":"GS Gerber","year":"1996","unstructured":"Gerber GS, Kim JH, Contreras BA, et al.: An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996, 47:840\u2013844.","journal-title":"Urology"},{"key":"157_CR27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","volume":"61","author":"RS Kirby","year":"2003","unstructured":"Kirby RS, Roehrborn CG, Boyle P, et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 2003, 61:119\u2013126.","journal-title":"Urology"},{"key":"157_CR28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","volume":"335","author":"H Lepor","year":"1996","unstructured":"Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia: Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996, 335:533\u2013539.","journal-title":"N Engl J Med"},{"key":"157_CR29","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387\u20132398.","journal-title":"N Engl J Med"},{"key":"157_CR30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","volume":"57","author":"P Kerrebroeck Van","year":"2001","unstructured":"Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414\u2013421.","journal-title":"Urology"},{"key":"157_CR31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","volume":"60","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG, Boyle P, Nickel JC, et al.; ARIA3001 ARIA3002 and ARIA3003 Study Investigators: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434\u2013441.","journal-title":"Urology"},{"key":"157_CR32","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","volume":"169","author":"A Athanasopoulos","year":"2003","unstructured":"Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled trial. J Urol 2003, 169:2253\u20132256.","journal-title":"J Urol"},{"key":"157_CR33","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","volume":"174","author":"KS Lee","year":"2005","unstructured":"Lee KS, Choo MS, Kim DY, et al.: Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005, 174:1334\u20131338.","journal-title":"J Urol"},{"key":"157_CR34","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA, Roehrborn CG, Rovner ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296:2319\u20132328","journal-title":"JAMA"},{"key":"157_CR35","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","volume":"102","author":"SA Kaplan","year":"2008","unstructured":"Kaplan SA, Roehrborn CG, Chancellor M, et al.: Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the international prostate symptom score. BJU International 2008, 102:1133\u20131139.","journal-title":"BJU International"},{"key":"157_CR36","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.juro.2008.05.050","volume":"180","author":"ES Rovner","year":"2008","unstructured":"Rovner ES, Kreder K, Sussman DO, et al.: Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008, 180:1034\u20131041.","journal-title":"J Urol"},{"key":"157_CR37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","volume":"56","author":"C Chapple","year":"2009","unstructured":"Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M and Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009, 56:534\u2013541.","journal-title":"Eur Urol"},{"key":"157_CR38","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4065\/83.9.1002","volume":"83","author":"SA MacDiarmid","year":"2008","unstructured":"MacDiarmid SA, Peters KM, Chen A, et al.: Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized double-blind placebo-controlled study. Mayo Clin Proc 2008, 83:1002\u20131010.","journal-title":"Mayo Clin Proc"},{"key":"157_CR39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.urology.2008.06.067","volume":"72","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG, Kaplan SA, Kraus SR, et al.: Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS including OAB. Urology 2008, 72:1061\u20131067.","journal-title":"Urology"},{"key":"157_CR40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2008.06.032","volume":"55","author":"CG Roehrborn","year":"2009","unstructured":"Roehrborn CG, Kaplan SA, Jones JS, et al.: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effect of prostate size. Eur Urol 2009, 55:472\u2013479.","journal-title":"Eur Urol"},{"key":"157_CR41","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.urology.2009.12.010","volume":"75","author":"DE Chung","year":"2010","unstructured":"\u2022 Chung DE, Te AE, Staskin DR, Kaplan SA: Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology 2010, 75:1144\u20131148. This is a good study examining efficacy of combination therapy of an antimuscarinic agent with a 5-\u03b1-reductase inhibitor.","journal-title":"Urology"},{"issue":"3","key":"157_CR42","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.juro.2009.05.038","volume":"182","author":"A Cameron","year":"2009","unstructured":"Cameron A, Clemens J, Latini J, McGuire E, . Combination Drug Therapy Improves Compliance of the Neurogenic Bladder. J Urol 2009;182(3):1062\u20137.","journal-title":"J Urol"},{"issue":"5","key":"157_CR43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.eururo.2008.01.007","volume":"53","author":"B Amend","year":"2008","unstructured":"Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert K. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53(5):1021\u20138.","journal-title":"Eur Urol"},{"key":"157_CR44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0022-5347(17)56918-9","volume":"121","author":"PH Abrams","year":"1979","unstructured":"Abrams PH, Farrar DJ, Turner-Warwick RT, et al.: The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979, 121:640\u2013642.","journal-title":"J Urol"},{"key":"157_CR45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(05)63949-3","volume":"169","author":"C Nunzio de","year":"2003","unstructured":"de Nunzio C, Franco G, Rocchegian A, et al.: The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003, 169:535\u2013539.","journal-title":"J Urol"},{"key":"157_CR46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(05)67450-2","volume":"164","author":"JL Donovan","year":"2000","unstructured":"Donovan JL, Peters TJ, Neal DE, et al.: A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. J Urol 2000, 164:65\u201370.","journal-title":"J Urol"},{"key":"157_CR47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11934-008-0050-z","volume":"9","author":"F Housami","year":"2008","unstructured":"Housami F, Abrams P: Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep 2008, 9:284\u2013290.","journal-title":"Curr Urol Rep"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-010-0157-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-010-0157-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-010-0157-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T14:24:03Z","timestamp":1559831043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-010-0157-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["157"],"URL":"https:\/\/doi.org\/10.1007\/s11934-010-0157-x","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,2]]}}}